On February 4, 2026 Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and Shanghai Lishan Biopharmaceuticals Co., Ltd. ("Lishan Biotech"), a China-based clinical-stage biotechnology company focused on innovative therapies in the fields of immunity and inflammation, reported that Biomica Ltd. ("Biomica"), Evogene’s subsidiary and Lishan Biotech entered into an exclusive worldwide licensing agreement for BMC128 (designated as LS-LBP-002 by Lishan Biotech), a first-in-class microbiome-based therapeutic designed to enhance anti-tumor immune activity. BMC128 was developed by Biomica and is currently completing a Phase 1 clinical study, showing promising early clinical results.

BMC128 is a live biopharmaceutical consortium composed of four human gut bacterial strains with defined functional capabilities that enhance responses to immunotherapy and stimulate anti-tumor immune activity. BMC128 is currently completing a Phase 1 clinical study in renal cell carcinoma and non-small cell lung cancer and has demonstrated encouraging early clinical promise. Results to date show an excellent safety and tolerability profile, together with early signs of efficacy, including a high proportion of patients with previously progressive disease achieving stable disease during treatment.

Under the agreement, Lishan Biotech will assume responsibility for global clinical development, manufacturing, and commercialization of BMC128. Biomica will be eligible to receive development milestone payments and royalties on future commercial sales, in accordance with an agreed-upon schedule.

Lishan Biotech plans to advance BMC128 into a Phase 2 clinical study and to pursue regulatory filings in both China and the United States for future commercialization.

Dr. Weijie Chen, Chairman of Lishan Biotech, stated: "This collaboration ensures that BMC128 continues to advance toward its next clinical milestones. We are impressed by the effects observed with BMC128 in lung and renal cancer patients who had experienced disease progression prior to treatment, and we look forward to advancing the program through further development and ultimately toward commercialization, for the benefit of cancer patients worldwide."

Ofer Haviv, CEO of Evogene and Biomica, commented: "We are pleased to partner with Lishan Biotech as BMC128 enters its next phase of development. Lishan Biotech’s strong development capabilities and commitment to innovative microbiome-based therapeutics position this program for meaningful value creation in difficult-to-treat cancers. As a major shareholder of Biomica, Evogene expects to benefit from BMC128’s future success."

Dr. Jing Bao, MD, a Director (Board Member) of Biomica Ltd with a PhD from the Weizmann Institute of Science, stated: "We are very pleased to see the execution of this meaningful and impactful collaboration agreement. This partnership brings together China’s clinical development capabilities with Israel’s innovation in microbiome science. We believe the success of this project will benefit patients worldwide and contribute to important breakthroughs in microbiome-based therapeutics."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, Evogene, FEB 4, 2026, View Source [SID1234662469])

On February 4, 2026 Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, reported a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The PaedNEO-VAX trial, funded by Providence Therapeutics, in combination with the Australian Government and a host of philanthropic donors, is the first multi-site pediatric study to test individualized mRNA vaccines designed specifically for each child’s cancer.

The trial is co-led by The University of Queensland and the South Australian Health and Medical Research Institute (SAHMRI) and will begin in March 2026 across seven pediatric hospitals in Queensland, South Australia, New South Wales, Victoria, and Western Australia. It is sponsored by the Australia & New Zealand Children’s Haematology and Oncology Group (ANZCHOG).

Providence Therapeutics is contributing its proprietary mRNA vaccine platform and manufacturing expertise to support the creation of personalized vaccines tailored to each patient’s tumor biology.

A New Frontier for Pediatric Brain Cancer

PaedNEO-VAX is open to children and adolescents with relapsed or refractory high-grade brain tumors, including high-grade glioma, diffuse midline glioma, medulloblastoma, and ependymoma.

Phase I will establish safety and optimal dosing, while Phase II will evaluate clinical outcomes such as disease progression, survival, and quality of life for patients and families.

Using genome sequencing and advanced data analysis, tumor-specific targets will be identified for each child. Customized mRNA vaccines will then be manufactured in Australia by Southern RNA, with an expected turnaround of approximately 10 weeks from enrollment to dosing.

"Where Hope and Science Intersect"

Providence’s interest in pediatric brain cancer is deeply rooted and personal.

"In 2013, my 13-year-old son Adam was diagnosed with glioblastoma multiforme (GBM) and given about 12 months to live. We were fortunate that we were able to get him into remission, and in 2015 I founded Providence Therapeutics with the mission to be ready if his cancer came back." said Brad Sorenson, Founder and CEO of Providence Therapeutics. "In early 2024 that horrible day came when his GBM recurred in his brainstem and throughout his spine, and we rushed to make a personalized vaccine for him. Adam was the first person to receive a Providence cancer vaccine, and he responded remarkably well. It is a rare good-news story, and he is still doing well today. Providence’s mission today is to see Adam’s success shared as widely as possible."

"This trial embodies our mantra of ‘Where Hope and Science Intersect.’ After more than a decade of scientific work, Providence is honoured to help bring hope to families facing devastating diagnoses. We are proud to support this world-first pediatric trial in Australia and hopeful that it will pave the way for similar initiatives in Canada and throughout the world."

An Open Invitation to Canada and the USA

Providence Therapeutics views this landmark trial as both a scientific breakthrough and a model for collaboration.

Following the Australian example, Providence welcomes dialogue with Canadian and USA leaders, cancer foundations, and cancer research organizations interested in exploring how similar cancer vaccine programs could be advanced in Canada and the USA.

This trial demonstrates what is possible when public investment, clinical leadership, and patient-driven innovation align — offering children and families facing the most aggressive cancers something profoundly needed: Hope.

(Press release, Providence Therapeutics, FEB 4, 2026, View Source [SID1234662484])

On February 4, 2026 GSK reported strong 2025 performance and re-affirms long-term outlooks.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sales, profit and earnings growth driven by strong Specialty Medicines performance
Total 2025 sales £32.7 billion +4% AER; +7% CER
Specialty Medicines sales £13.5 billion (+17%); Respiratory, Immunology & Inflammation £3.8 billion (+18%); Oncology
£2.0 billion (+43%); HIV sales £7.7 billion (+11%)
Vaccines sales £9.2 billion (+2%); Shingrix £3.6 billion (+8%); Meningitis vaccines £1.6 billion (+12%); and Arexvy £0.6
billion (+2%)
General Medicines sales £10.0 billion (-1%); Trelegy £3.0 billion (+13%)
Total operating profit >100% and Total EPS >100% driven by lower Significant legal expenses, lower CCL charges and
higher other operating income, partly offset by intangible asset impairments
Core operating profit +11% and Core EPS +12% reflecting Specialty Medicines and Vaccines growth, SG&A productivity,
higher royalty income and disciplined increased investment in R&D portfolio progression in Oncology and Vaccines
Cash generated from operations of £8.9 billion with free cash flow of £4.0 billion
2025 Q4 2025
£m % AER % CER £m % AER % CER
Turnover 32,667 4 7 8,618 6 8
Total operating profit 7,932 97 >100 1,100 58 65
Total operating margin % 24.3% 11.5ppts 11.9ppts 12.8% 4.2ppts 4.6ppts
Total EPS 141.1p >100 >100 15.8p 56 65
Core operating profit 9,783 7 11 1,634 14 18
Core operating margin % 29.9% 0.7ppts 1.1ppts 19.0% 1.4ppts 1.6ppts
Core EPS 172.0p 8 12 25.5p 10 14
Cash generated from operations 8,943 14 2,689 4

R&D momentum further strengthens growth prospects:
Strong pipeline progress in 2025:
5 major FDA approvals: Blenrep, Exdensur, Nucala COPD, Penmenvy, Blujepa
7 pivotal trial starts including: risvutatug rezetecan (ris-rez) for 2L/3L ES-SCLC; efimosfermin in MASH; Exdensur for COPD; and velzatinib for 2L GIST
RI&I and Oncology pipelines strengthened:
New assets acquired: efimosfermin (liver disease); velzatinib/IDRX-42 (gastrointestinal cancer); and agreement to acquire ozureprubart (food allergies)
Agreements/collaborations with Hengrui (RI&I and oncology); Empirico (COPD); and LTZ Therapeutics (oncology)
29 projects currently in clinical development for RI&I and Oncology diseases
Further pipeline acceleration expected in 2026:
2 new major product approvals expected: bepirovirsen, potential first-in-class treatment for chronic hepatitis B; and tebipenem, first oral treatment for complicated UTIs
5 pivotal readouts: bepirovirsen for chronic hepatitis B (positive); camlipixant (chronic cough); Jemperli (rectal cancer); Q4M HIV PrEP; and Exdensur for EGPA
10 pivotal trial starts, including for ADCs B7-H3 (ris-rez) & B7-H4 (mocertatug rezetecan, mo-rez) to treat multiple cancer types

Continued commitment to shareholder returns
Q4 2025 dividend of 18p declared; 66p FY 2025; 70p expected for full year 2026
£1.4 billion executed to date as part of the £2 billion share buyback programme announced at FY 2024
2026 guidance and 2031 sales outlook reaffirmed
Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9%
2031 sales outlook of more than £40 billion

Luke Miels, Chief Executive Officer, GSK:
"GSK delivered another strong performance in 2025, driven mainly by Specialty Medicines, with double-digit sales growth in
Respiratory, Immunology & Inflammation (RI&I), Oncology and HIV. Good R&D progress also continued, with 5 major product
approvals achieved and several acquisitions and new partnerships completed to strengthen the pipeline further in oncology and RI&I. We expect this positive momentum to continue in 2026, which will be a key year of execution and operational delivery with strong focus on commercial launches and accelerating R&D. We are well placed to move forward in this next phase for GSK – to deliver our outlooks – and to create new value for patients and shareholders."

Assumptions and cautionary statement regarding forward-looking statements
The Group’s management believes that the assumptions outlined above are reasonable, and that the guidance,
outlooks, and expectations described in this report are achievable based on those assumptions. However, given the
forward-looking nature of these guidance, outlooks, and expectations, they are subject to greater uncertainty, including
potential material impacts if the above assumptions are not realised, and other material impacts related to foreign
exchange fluctuations, macro-economic activity, the impact of outbreaks, epidemics or pandemics, changes in
legislation, regulation, government actions and policies, including the impact of any potential tariffs or other restrictive
trade policies on the Group’s products, or intellectual property protection, product development and approvals, actions
by our competitors, and other risks inherent to the industries in which we operate.

This document contains statements that are, or may be deemed to be, "forward-looking statements". Forward-looking
statements give the Group’s current expectations or forecasts of future events. An investor can identify these
statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’, ‘outlook’, ‘aim’, ‘ambition’, ‘could’, ‘goal’, ‘may’,
‘seek’, ‘should’ and other words and terms of similar meaning in connection with any discussion of future operating or
financial performance. In particular, these include statements relating to future actions, prospective products or
product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the
outcome of contingencies such as legal proceedings, dividend payments and financial results. Other than in
accordance with its legal or regulatory obligations (including under the Market Abuse Regulation, the UK Listing Rules
and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no
obligation to update any forward-looking statements, whether as a result of new information, future events or
otherwise. The reader should, however, consult any additional disclosures that the Group may make in any documents
which it publishes and/or files with the SEC. All readers, wherever located, should take note of these disclosures.
Accordingly, no assurance can be given that any particular expectation will be met and readers are cautioned not to
place undue reliance on the forward-looking statements.

All guidance, outlooks and expectations should be read together with the guidance and outlooks, assumptions and
cautionary statements in this full year and Q4 2025 earnings release and in the Group’s 2024 Annual Report on Form
20-F.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to
factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of
important factors, including those in this document, could cause actual results to differ materially from those expressed
or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under ‘Risk
Factors’ in the Group’s Annual Report on Form 20-F for 2024. Any forward-looking statements made by or on behalf of
the Group speak only as of the date they are made and are based upon the knowledge and information available to
the Directors on the date of this report.

(Press release, GlaxoSmithKline, FEB 4, 2026, View Source [SID1234662470])

On February 4, 2026 Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, reported the closing of a $52 million Series A extension.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New investor Andreessen Horowitz (a16z) joined Third Arc Bio’s existing world-class investor syndicate to further validate the company’s approach to deliver transformational therapies for patients. As part of the financing, a16z General Partner, Jorge Conde, joins Third Arc Bio’s Board of Directors. Proceeds from the financing will enable Third Arc Bio to accelerate its I&I portfolio and deliver additional oncology programs into the clinic.

"Third Arc represents a shift toward more precise immune modulation—moving beyond systemic exposure to therapies designed to deliver highly controlled biological effects at sites of disease," said Jorge Conde, General Partner at a16z. "The company’s platforms, combined with a team that has repeatedly translated complex immunology into approved medicines, reflect a rigorous, patient-driven approach to building biologics that can improve both efficacy and safety across oncology and immune-mediated disease."

Since its launch in 2022 with seed financing from Omega Funds, Third Arc Bio has assembled a highly experienced team with a proven track record of drug discovery and development, alongside an innovative platform and a pipeline of multispecific antibodies. The company’s lead asset, ARC101, is a bispecific T cell engager targeting CLDN6 currently in Phase 1 dose escalation in patients with advanced solid tumors.

"This financing allows us to maintain momentum across our expanding oncology portfolio while rapidly advancing our next-generation I&I assets into first-in-human studies," said Peter F. Lebowitz, MD, PhD, Chief Executive Officer of Third Arc Bio. "By parallel-tracking programs, we can more efficiently validate the full potential of our platforms, rapidly generate proof-of-concept data, and deliver innovative therapies for patients with significant unmet need."

Third Arc Bio’s approach to I&I is anchored by its ARCTag (Tethered Agonist) Platform, which leverages multispecific antibodies to localize immune modulation directly to sites of disease. This targeted activity represents a meaningful advance beyond conventional systemic autoimmune therapies, offering the potential for enhanced efficacy and therapeutic index.

(Press release, Third Arc Bio, FEB 4, 2026, View Source;inflammation-portfolio-302678506.html [SID1234662485])

On February 4, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, reported the closing of an exclusive license with Otsuka Pharmaceutical Co., Ltd (Otsuka) for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumours (GIST). The compound also has the potential to be useful in additional indications. In Biodexa’s pipeline, OPB-171775 is to be coded MTX240.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stephen Stamp, Chief Executive Officer of Biodexa commented "MTX240 represents a fantastic opportunity for Biodexa. Its unique molecular glue mechanism of action separates MTX240 from current standard of care with the potential to benefit a broad spectrum of GIST patients, including those with TKI-resistant disease. MTX240 strategically aligns with our emerging GI/oncology pipeline which includes our ongoing Phase 3 development of eRapa in Familial Adenomatous Polyposis."

About MTX240, its Unique Mechanism of Action and Clinical Rationale

Molecular glue technology represents a novel approach that induces targeted protein interactions, offering a distinct mechanism of action to conventional kinase inhibitors for rare oncology indications.

GIST is driven by activating mutations in the KIT receptor tyrosine kinase. While tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib are reported to have significantly improved outcomes for GIST patients, resistance almost always develops through secondary KIT mutations or activation of alternative signalling pathways. This represents a substantial clinical challenge with limited therapeutic options for patients once they have cycled through the available TKIs.

MTX240 acts as a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT signalling. By triggering cell death through this alternative pathway, MTX240 is designed to overcome the resistance mechanisms that render TKI-resistant GISTs refractory to conventional kinase inhibitors. This novel mechanism may provide clinical benefit for a significant proportion of GIST patients, not only those who have developed resistance to TKIs.

MTX240, referenced as OPB-171775 in the charts, and vehicle were administered once daily for 21 days. Imatinib was administered twice daily for 21 days. The values represent mean tumor volumes +/- standard error of the mean GS5107 (n=3), GS5108 (n=5), GS11353 (n=5).

PDX models use actual tumor tissue harvested from patients, preserving the genetic complexity and treatment resistance patterns of real human cancers. This makes PDX studies far more predictive of human clinical outcomes because they bridge the gap between laboratory discovery and clinical trials5.

Addressing Unmet Medical Need in GIST

GIST is a rare gastrointestinal malignancy affecting approximately 3,000-4,000 patients annually in the United States2, with a significant unmet medical need for patients who develop TKI resistance. Approximately 10-15%3. of GIST patients are either primarily refractory, or develop secondary resistance, to available TKIs, and options for these patients remain limited. MTX240’s novel mechanism represents a potentially differentiated therapeutic approach that circumvents conventional resistance pathways and aligns with Biodexa’s strategic focus on rare disease development and addressing important clinical gaps.

The global GIST market is valued at approximately USD 1.3 billion and is expected to grow at 6-10% annually through 2032, driven by rising incidence and emerging therapeutic options targeting treatment-resistant disease4.

GIST qualifies for orphan drug designation in major regulatory jurisdictions, offering potential regulatory advantages and incentives to support drug development.

Licensing and Collaboration Agreement

Under the terms of the license agreement Biodexa has the exclusive rights to develop and commercialize MTX240 globally with the exception of Japan where Otsuka retains its rights. The agreement includes an upfront fee and additional development and regulatory milestones. In addition, tiered royalties in the mid-single digit range are payable on net sales of MTX240.

MTX240 benefits from composition of matter patents in the US, Europe, Japan and various other countries extending through 2037 without any patent term extension.

(Press release, Biodexa Pharmaceuticals, FEB 4, 2026, View Source [SID1234662471])